A cannabinoid formulation comprising cannabinoid concentrate and beeswax, or a beeswax analogue, in a ratio of 30 : 1 to 40 : 1 by weight. Preferably the ratio is 35 : 1. The vaporizable formulation is packaged in a single use glass vial and used for pulmonary administration to a patient. The glass vial is made from borosilicate glass, has a cylindrical shape, an open end and no lid. The vial preferably has a uniform wall thickness of 0.02 inches. The formulation forms a wax seal at room temperature to eliminate any need for a lid. The formulation can be directly vaporized from the glass vial to eliminate transfer of the formulation to another container, to eliminate mess, to enable precise dosing, and to enable easy recycling and disposal of the vial after use.